Stephanie Jordan
Postdoctoral Scholar, Emergency Medicine
Bio
Stephanie's research focuses on social and environmental determinants of health, U.S. public health policy, health services implementation science, and global health. Her research employs primarily quantitative methods. She received her PhD in Public Policy and Sociology from Duke University, where her dissertation analyzed the population health impacts of U.S. state public service expenditures on social, environmental, and healthcare services.
Honors & Awards
-
German-American Academic Exchange Association RISE Scholar, German Academic Exchange Association (2018)
-
Barry Goldwater Scholarship, Barry Goldwater Scholarship and Excellence in Education Foundation (2019)
Professional Education
-
PhD, Duke University (2025)
-
BA, Middlebury College (2020)
All Publications
-
Assessing an educational strategy to improve community health provider-led provision of cervical cancer screening services in western Kenya: A secondary analysis of the Elimisha-HPV cluster-randomized controlled trial.
Global health & medicine
2026; 8 (5): 332-341
Abstract
Cervical cancer disproportionately impacts women in low- and middle-income countries (LMICs), where over 90% of global cervical cancer deaths occur. Lay health workers, such as community health promoters (CHPs), with appropriate training and support, can play a pivotal role in cervical cancer prevention. Our team developed a multi-level intervention, Elimisha-HPV, to support CHP-delivered human papillomavirus (HPV) testing in Kenya. The present analysis evaluates impact of Elimisha-HPV on the following CHP outcomes: i) knowledge of screening delivery and privacy, confidentiality, and professionalism; ii) stigma associated with cervical cancer, human immunodeficiency virus (HIV), and HPV; and iii) confidence to counsel in screening delivery. We used descriptive statistics and linear mixed effects regression models to evaluate intervention effects (intervention group, n = 64; control group, n = 60). For knowledge and privacy, no statistically significant effects were observed (knowledge: β= -0.08 [95% CI, -0.22 to 0.07]; privacy: β= 0.04 [95% CI, -0.05 to 0.13]). No statistically significant intervention effects were observed for stigma associated with cervical cancer, HIV, or HPV (cervical cancer: β= 0.02 [95% CI, -0.13 to 0.16]; HIV: β= 0.01 [95% CI, -0.11 to 0.13]; HPV: β= 0.02 [95% CI, -0.11 to 0.14]). For the confidence to counsel Likert scale-style questions, evaluated using descriptive and regression approaches, proportional increases were observed across both arms, but the main effect was not statistically significant ( β= 0.01 [95% CI, -0.09 to 0.11]). Our findings align with previous work demonstrating that stigma surrounding cervical cancer in LMICs is difficult to effectively influence, and provide a foundation for shaping future stigma-reduction campaigns. ClinicalTrials.gov identifier: NCT05736588.
View details for DOI 10.35772/ghm.2026.01062
View details for PubMedID 42959212
View details for PubMedCentralID PMC13716680
-
Assessing an educational strategy to improve community health provider-led provision of cervical cancer screening services in western Kenya: A secondary analysis of the Elimisha-HPV cluster-randomized controlled trial
GLOBAL HEALTH & MEDICINE
2026
View details for DOI 10.35772/ghm.2026.01062
View details for Web of Science ID 001884036900001
-
Heterogeneous Treatment Effects of a Prescription for Produce Subsidy on Diabetes Care Management.
Diabetes, obesity, and cardiometabolic CARE
2026; 1 (3): 468-477
Abstract
"Food Is Medicine" approaches are popular disease management strategies for patients experiencing food insecurity (FI) and diet-sensitive conditions; however, few studies consider heterogeneous treatment effects (HTE) across patient subpopulations. We estimate HTE of a prescription for produce (PRx) tested within a randomized controlled trial of patients with diabetes at risk of FI.We use machine learning to estimate HTE of a PRx conducted within an integrated health system, academic medical center, and primary care network in the southeastern U.S. This trial included 2,155 patients enrolled in the health system's diabetes registry with at least one hemoglobin A1c (HbA1c) measurement in the prior year and at-risk status for FI. Participants received $80/month for 12 months on a debit card covering fruit and vegetable purchases. Outcomes included HbA1c change (post- minus preintervention) and any postintervention emergency department (ED) utilization.For HbA1c, the largest negative standardized difference in HbA1c change between intervention arms was observed among participants with HDL cholesterol >50.67 mg/dL and triglycerides >82.5 mg/dL (estimate [SE] -0.25% [0.12], -2.7 mmol/mol [1.3]; P = 0.019). For ED visits, the largest reduction in probability of any postintervention visits between arms was observed among individuals with low outpatient (OP) utilization, nonprivate and non-Medicare insurance, LDL cholesterol >78.5 mg/dL, and age >50.5 years (estimate [SE] -0.2 [0.05]; P < 0.001).Our findings suggest that social factors (e.g., age and OP utilization) and clinical factors (e.g., cholesterol) may impact PRx effectiveness for diabetes management.
View details for DOI 10.2337/doc26-0005
View details for PubMedID 42890552
View details for PubMedCentralID PMC13671911
https://orcid.org/0000-0002-7448-0479